Medicare

The article discusses the benefits of whole-body treatment for health, emphasizing that interconnected systems like the gut can impact hormones, metabolism, and immunity. Experts argue that focusing on the body as a unified system, rather than isolated symptoms, may improve outcomes, especially as people age. Challenges include fragmented medical care and Medicare's focus on disease management over holistic approaches.

Dr. Rhea Rogers advocates for a whole-body approach to health, emphasizing interconnected systems like the gut's role in hormonal and immune issues. Experts highlight challenges with aging, including fragmented care and Medicare's focus on disease management over holistic treatment. Patients are urged to advocate for themselves and seek comprehensive solutions.

Dr. Rhea Rogers advocates for whole-body health approaches, arguing that interconnected systems like the gut influence hormonal and immune function. Experts like Amy O’Rourke and Katherine Ambrose highlight systemic barriers in healthcare, such as Medicare's focus on disease management, and urge individuals to advocate for holistic solutions.

Thousands of Medicare beneficiaries enrolled in zero-premium drug plans from Wellcare and other insurers lost coverage after their premiums increased and they failed to pay, leading to termination. Jude Pare, a beneficiary, faced coverage cancellation and potential life-threatening risks due to lost access to critical medication.

The article discusses gaps in Medicare coverage for aging individuals, including caregiving, dental care, and home modifications. It highlights a nonprofit combating loneliness through random acts of social connection and provides tips for caregivers of loved ones with dementia. A couple’s weekly bookstore visits illustrate long-term relationship strategies.

The article highlights four biotech updates: Medicare proposing cuts to 340B payments, Republicans advocating for diversity in clinical trials, former surgeon general Jerome Adams advising on peptides regulation, and Novartis acquiring Myricx Bio for $1.1 billion to expand its cancer drug development. Anthropic CEO Dario Amodei expresses cautious optimism about AI's role in biotechnology.

Advances in healthcare technology and new care delivery models are enabling seniors to age at home, supported by policies like Medicare's Acute Hospital Care at Home program and the GUIDE dementia model. However, home health services face fraud risks, with examples like Los Angeles County's overconcentration of hospice providers and fraudulent billing networks.

Thousands of Medicare beneficiaries lost drug coverage after failing to pay increased premiums they were unaware of, resulting in coverage loss until 2027 due to as little as $8 in unpaid charges.

Thousands of Medicare beneficiaries lost their drug coverage due to small delinquent payments, unaware their zero-dollar premiums had increased. Most cannot regain coverage until 2027.

John Goldstein, a 75-year-old retiree in Newark, New Jersey, spends $150 weekly on groceries by skipping meat and avoiding restaurants to manage rising healthcare costs. He saves money through coupon use, shopping at specific stores like ShopRite, and growing fresh herbs and vegetables at home.

Medicare is now covering some GLP-1 weight loss drugs at a cost of $50 for many older Americans, making these previously expensive medications more affordable.

The U.S. debt, once a masterstroke under Alexander Hamilton's 1790 plan to consolidate Revolutionary War debts, established the nation's creditworthiness and financial power. Today, U.S. debt exceeds $39 trillion, raising concerns over sustainability as interest costs surge and fiscal policies remain unaddressed.

President Donald Trump signed the Big Beautiful Bill Act one year ago, which the Trump administration claims has reduced Medicaid costs and prevented $42 billion in fraudulent health care spending. Democrats argue the law weakens health care programs for low-income Americans, while Dr. Mehmet Oz, administrator of Medicare and Medicaid, defends stricter work requirements and enrollment changes. Estimates suggest over $1 trillion was cut from federal health care spending, with 4.8 million Americans losing Medicaid coverage.

Medicare is now covering some GLP-1 agonists for weight loss at a reduced cost of $50 for eligible older Americans. The federal government began offering these medications to certain Medicare beneficiaries this week, making previously expensive treatments more affordable.

A Prior Auth Bill with wide support and no cost is being considered for passage in Congress. Peggy Tighe of the Regulatory Relief Coalition, a group of physician specialty organizations advocating for reduced Medicare regulatory burdens, expresses hope for the bill's success.

Medicare has initiated a GLP-1 pilot program. The article highlights that Medicare coverage of these weight loss drugs could benefit millions of people.

Medicare proposes reducing payments to hospitals for drugs under the 340B program by over a third, citing surveys showing some patients paid more than hospitals. The change, part of a hospital outpatient payment rule, faces criticism from nonprofit and academic hospital groups, who argue it will harm safety-net providers, as only nonprofit facilities qualify for 340B discounts.

AI could reduce the U.S. deficit by $2.2 trillion by 2036 through productivity gains, but economists warn over half of these savings might be offset by AI-driven disruptions. A study by Brookings and the Federal Reserve highlights potential fiscal benefits from AI but cautions against compounding side effects, similar to the 1990s Internet boom's eroded gains.

The Trump administration proposes a rule to prevent hospitals from charging markups on discounted drugs for Medicare patients, aiming to save $1.1 billion annually. Former CIA Director John Brennan sued the administration over record preservation, while an FBI agent in Chicago resigned amid workforce changes under Director Kash Patel. The American Hospital Association warned the rule could harm hospitals' financial stability.

Medicare is now covering some GLP-1 weight loss drugs for $50, making them more affordable for older Americans. These drugs were previously popular and expensive.

Medicare is now covering some GLP-1 weight loss drugs at a cost of $50, making these previously expensive treatments more affordable for many older Americans.

The Trump administration is proposing a rule to prevent hospitals in the 340B program from billing insurers above discounted drug costs for Medicare patients, aiming to save $1.1 billion annually. The rule targets hospitals that currently markup drug prices, which could reduce patient costs but may also impact hospital revenues and services.

The Trump administration proposes a rule to prevent hospitals in the 340B program from charging markups on discounted drugs for Medicare patients, aiming to save $1.1 billion annually. The rule would adjust Medicare reimbursement formulas for these hospitals, with an example showing potential savings on the prostate cancer drug Lupron Depot.

Medicare will start covering weight-loss drugs via a temporary pilot program on July 1, allowing millions of enrollees access to medications like Wegovy and Zepbound at significantly reduced costs under a deal with Eli Lilly and Novo Nordisk. The program aims to address obesity as a treatable disease, offering seniors like Mary and Jeff Abrahamson affordable options that improve health outcomes.

A new Medicare program may allow coverage for certain weight loss medications, which are currently excluded under existing law. Juliette Cubanski of KFF discusses the potential impact of this change.

Medicare has started covering obesity drugs for the first time, and companies like Walmart and CVS Health are assisting seniors in navigating this coverage.

A Medicare pilot program expands access to GLP-1 weight-loss medications like Wegovy and Zepbound for some seniors, offering subsidies as high as $50 per month. The program, running through 2027, requires a BMI above 35 or specific weight-related conditions for eligibility, though 6 million Medicare Part D recipients who might otherwise qualify will remain excluded. Concerns persist about potential bone and muscle density loss from rapid weight loss, but medical professionals suggest exercise can mitigate risks.

Minnesota counties are overwhelmed by Medicaid renewal bureaucracy due to new federal requirements under HR 1, which mandate shorter reporting cycles and stricter verification. The process has led to unnecessary paperwork for eligible residents, increased administrative costs, and workforce strain in local offices.

The article discusses Medicare's GLP-1 Bridge program, which provides coverage for GLP-1 receptor agonists to manage diabetes and obesity. It aims to address gaps in access to these medications for eligible beneficiaries.

Medicare is offering select GLP-1 weight loss drugs for $50/month through a temporary trial until 2027, with eligibility based on BMI and specific health conditions. Covered medications include Eli Lilly's Foundayo and Zepbound, and Novo Nordisk's Wegovy, but exclusions apply for those with diabetes or sleep apnea.

Nutex Health, a hospital in New Mexico, does not contract with Medicare and is therefore not subject to federal regulations requiring treatment for all patients. The facility is alleged to have exploited a loophole in these regulations.

Medicare will now cover some GLP-1 medications for weight loss starting Wednesday. CBS News medical correspondent Dr. Celine Gounder provides an explanation of the policy change.

The article discusses the evolving debate around birthright citizenship and mentions Medicare's coverage of weight loss drugs. Demonstrators gathered outside the U.S. Supreme Court on April 1, 2026, to support birthright citizenship.

Medicare is providing beneficiaries access to popular obesity drugs with a $50 monthly copay. The program requires patients to meet specific criteria and is a temporary initiative set to last through 2027.

A new federal program allows some Medicare Part D beneficiaries to obtain expensive weight loss drugs at $50 per month. Medicare is rolling out this initiative, which may lead to challenges for Michigan doctors.

Medicare is a federal health insurance program for those aged 65 and older, as well as individuals under 65 with disabilities or conditions like end-stage renal disease or ALS. It includes parts A, B, and D for hospital, outpatient, and prescription drug coverage, with costs varying annually. Medicare Advantage (Part C) offers an alternative through private plans, often with network restrictions.

Northwestern State University's proposed law school faces stalled approval despite President Jimmy Genovese's efforts, while Medicare begins covering GLP-1 weight-loss drugs for obesity treatment. The Trump administration plans to allocate $500 million to support smaller meatpackers amid high beef prices.

Millions of Americans can now get Medicare coverage for GLP-1 drugs to treat weight loss starting this week. Previously, Medicare only covered these drugs for conditions like Type 2 diabetes, sleep apnea, and stroke or heart-attack risk.

Medicare will cover GLP-1 weight-loss treatments through a temporary pilot program starting July 1, allowing eligible participants to pay a $50 monthly co-pay. The program includes Eli Lilly’s Zepbound and Foundayo and Novo Nordisk’s Wegovy, with coverage ending by 2027 due to federal law restrictions. Eligibility requires a BMI of 35 or higher (or 30 with specific health conditions), and prior authorization is needed.

Medicare will begin covering obesity drugs for the first time, potentially expanding access for seniors and creating new patient opportunities for Novo Nordisk and Eli Lilly.